Cumberland Pharmaceuticals Inc. CPIX
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 163.90K | 9.55M | 8.29M | 380.80K | 166.60K |
| Total Other Revenue | -- | 4.13M | -- | -- | -- |
| Total Revenue | 163.90K | 13.68M | 8.29M | 380.80K | 166.60K |
| Cost of Revenue | -- | 2.24M | 988.80K | -- | -- |
| Gross Profit | 163.90K | 11.44M | 7.30M | 380.80K | 166.60K |
| SG&A Expenses | 2.32M | 10.25M | 7.01M | 2.66M | 2.20M |
| Depreciation & Amortization | 7.00K | 1.01M | 1.01M | 5.80K | 6.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.10M | 15.05M | 10.26M | 3.50M | 2.89M |
| Operating Income | -2.93M | -1.37M | -1.97M | -3.12M | -2.72M |
| Income Before Tax | -2.85M | -1.41M | -1.94M | -2.99M | -2.60M |
| Income Tax Expenses | 3.90K | 23.20K | 5.70K | 5.70K | 5.70K |
| Earnings from Continuing Operations | -2.86M | -1.43M | -1.95M | -3.00M | -2.61M |
| Earnings from Discontinued Operations | -428.80K | -- | -- | 2.26M | 3.86M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.60K | 17.00K | 8.30K | -5.50K | 8.90K |
| Net Income | -3.29M | -1.41M | -1.94M | -740.70K | 1.26M |
| EBIT | -2.93M | -1.37M | -1.97M | -3.12M | -2.72M |
| EBITDA | -1.66M | -329.30K | -927.50K | -2.09M | -1.69M |
| EPS Basic | -0.22 | -0.09 | -0.13 | -0.05 | 0.08 |
| Normalized Basic EPS | -0.12 | -0.06 | -0.08 | -- | -0.11 |
| EPS Diluted | -0.22 | -0.09 | -0.13 | -0.05 | 0.08 |
| Normalized Diluted EPS | -0.12 | -0.06 | -0.08 | -- | -0.11 |
| Average Basic Shares Outstanding | 14.96M | 14.96M | 14.96M | 14.96M | 14.94M |
| Average Diluted Shares Outstanding | 14.96M | 14.96M | 14.96M | 14.96M | 14.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |